Listing 7.05 in 2026: How Social Security Decides Sickle Cell, Thalassemia, and Hemolytic Anemia Claims Under Paragraph A 6 Pain Crises, Paragraph B 3 Hospitalizations, Paragraph C Hemoglobin Under 7.0, and Paragraph D Beta Thalassemia Major

Published June 21, 2026 by Anthony Albert, Benefits Research Director, Disability Exchange. Sources cited from SSA Blue Book Listing 7.05, 20 CFR Part 404 Subpart P Appendix 1, Section 7.00C preamble, SSR 17-3p on evaluating sickle cell disease, POMS DI 34132 hematological listings, and the Federal Register revised hematological criteria from 2015.

About 100,000 Americans live with sickle cell disease, and about 1,000 babies are born with it each year. Thalassemia affects another 1,000 Americans with the transfusion-dependent form and several thousand more with milder variants. Hereditary spherocytosis, glucose-6-phosphate dehydrogenase deficiency, and autoimmune hemolytic anemias add to the population. All of these chronic hemolytic anemias fall under Listing 7.05 in the SSA Blue Book.

The initial denial rate on sickle cell SSDI claims sits above 60 percent at most state DDS offices, even though many of these claimants have years of documented pain crises and hospitalizations. The reason almost always comes back to the listing's counting rules. Listing 7.05 is a numbers listing. Six crises a year, three hospitalizations a year, three hemoglobin readings of 7.0 g/dL or less in a year. If the file does not document the exact frequency with the exact gaps between events, the listing is not met and DDS denies at step 3.

This is the deep walkthrough. We will go through Listing 7.05 paragraph by paragraph, what a documented vaso-occlusive crisis has to look like under paragraph A, what counts as a hospitalization under paragraph B (including the 48 hour rule and emergency department time), the hemoglobin rules under paragraph C, the lifelong transfusion threshold under paragraph D, the residual case under Listing 7.18, and the records that move the needle.

Where Listing 7.05 sits in the rules

Listing 7.05 is part of Section 7.00 of the adult Listing of Impairments, codified at 20 CFR Part 404, Subpart P, Appendix 1. Section 7.00 covers hematological disorders. The full title of 7.05 is "Hemolytic anemias, including sickle cell disease, thalassemia, and their variants." The listing has four independent paths labeled A through D. You only need to meet one.

The 7.00C preamble defines hemolytic anemia as the premature destruction of red blood cells. Sickle cell disease is the most common example. Other examples are thalassemia (alpha and beta variants), hereditary spherocytosis, G6PD deficiency, paroxysmal nocturnal hemoglobinuria, and autoimmune hemolytic anemia. All of these conditions can qualify under 7.05 if the criteria are met.

SSR 17-3p, issued in March 2017 and still in force in 2026, gives the operating rules for evaluating sickle cell disease under 7.05. The ruling explains what counts as a vaso-occlusive crisis, what counts as a hospitalization, and how to handle chronic versus acute pain. It is the single most useful SSA document on sickle cell claims and worth a careful read if you are building a case.

Other hematological listings that overlap with 7.05 include 7.08 disorders of thrombosis and hemostasis (hemophilia, thrombocytopenia), 7.10 disorders of bone marrow failure (myelodysplastic syndromes, aplastic anemia), 7.17 hematological disorders treated by bone marrow or stem cell transplantation, and 7.18 repeated complications of hematological disorders. The residual case under 7.18 is the rescue path for sickle cell claimants who do not quite meet 7.05.

Listing 7.05A: 6 documented painful crises in 12 months

Listing 7.05A is met when there are documented painful (vaso-occlusive) crises requiring parenteral (intravenous or intramuscular) narcotic medication, occurring at least 6 times within a 12 month period with at least 30 days between crises.

Four pieces have to be in place. First, the crisis has to be vaso-occlusive, which means caused by sickled red blood cells blocking blood flow. The 7.00C2 preamble accepts the diagnosis once hemoglobin electrophoresis confirms sickle cell disease. Second, the crisis has to require parenteral narcotic medication. Oral opioids do not count. The crisis has to be severe enough that IV or IM administration was needed.

Third, the crisis has to be documented. A medical record from the ER, urgent care, specialty sickle cell disease center, or hospital admission has to confirm the date, the symptoms, and the medication route. Without that paper trail, the crisis does not count even if you remember it clearly.

Fourth, the crises have to be at least 30 days apart. Two crises 25 days apart count as one event for listing purposes. The rule exists to prevent stacking of related episodes from the same underlying flare. If your file has 10 crises over 12 months but 4 of them are clustered within a 30 day window, the count is functionally 6 events, not 10. Walk through the dates carefully.

The most common path to approval for adult sickle cell patients is paragraph A. The hardest part is usually pulling together the records from multiple ERs and urgent cares. Many sickle cell patients go to different facilities depending on where they are when the crisis hits. Centralize the records. Request from every ER, every urgent care, and the primary sickle cell center.

Listing 7.05B: 3 hospitalizations in 12 months

Listing 7.05B is met when complications of hemolytic anemia require at least 3 hospitalizations within a 12 month period, occurring at least 30 days apart, with each hospitalization lasting at least 48 hours. Emergency department time immediately before the hospitalization counts toward the 48 hours if the ER visit transitioned directly into the inpatient stay.

The 7.00C2 preamble lists examples of complications that count: osteomyelitis, vaso-occlusive crisis, pulmonary infections or infarctions, acute chest syndrome, pulmonary hypertension, chronic heart failure, gallbladder disease, hepatic failure, renal failure, nephrotic syndrome, aplastic crisis, and stroke. The hospitalizations do not have to be for the same complication. Three hospitalizations for three different sickle cell complications all count.

The 48 hour rule is the most common trip wire. A 24 hour observation stay does not meet the threshold. A 30 hour ER hold followed by a 24 hour inpatient stay (totaling 54 hours) does count if the ER and the admission were continuous. Pull the records carefully. Time stamps on the ER triage note, the inpatient admission order, and the discharge note tell the story.

Specialty sickle cell disease centers count as hospitals for this purpose. SSA accepts hours of treatment at a specialty sickle cell center as equivalent to ER time. If your sickle cell center has an infusion unit where you receive IV fluids and IV narcotics during a crisis, those hours count toward the 48 hour requirement.

Listing 7.05C: hemoglobin 7.0 g/dL or less, 3 times in 12 months

Listing 7.05C is met when hemoglobin measurements are 7.0 g/dL or less, occurring at least 3 times within a 12 month period with at least 30 days between measurements. Normal adult hemoglobin is roughly 12 to 16 g/dL. A hemoglobin of 7.0 g/dL or less indicates severe anemia.

The 7.00C5 preamble specifically allows hemoglobin to be measured during a sickle cell crisis or other complication. You do not have to wait until you are at baseline. If your hemoglobin dropped to 6.5 g/dL during a pain crisis hospitalization and you had similar drops on two other separate occasions at least 30 days apart, paragraph C is met.

This is the most useful path for patients with hemolytic anemias other than sickle cell, including autoimmune hemolytic anemia, hereditary spherocytosis, and severe G6PD deficiency. The crisis count under paragraph A is sickle cell focused. The hospitalization count under paragraph B can apply but is harder to meet. The hemoglobin count under paragraph C applies to any chronic hemolytic anemia where the destruction outpaces the production.

The catch is that many sickle cell patients have a baseline hemoglobin in the 7.5 to 9.0 g/dL range without quite dropping to 7.0. They are anemic, but not at the listing threshold. If your CBCs are running 7.5 to 8.5 most of the time, paragraph C is unlikely. Pivot to A, B, or the residual 7.18 case.

Listing 7.05D: beta thalassemia major requiring lifelong transfusions

Listing 7.05D is met when there is beta thalassemia major requiring lifelong red blood cell transfusions at least once every 6 weeks to maintain life. This is the rarest path. Beta thalassemia major is the most severe form of thalassemia, where the bone marrow cannot produce enough functional red blood cells, and the patient becomes transfusion-dependent within the first 2 years of life.

The 7.00C7 preamble draws a hard line. Prophylactic RBC transfusions in sickle cell disease (used to prevent stroke or other complications) do not count toward 7.05D. The listing is reserved for the patient whose marrow simply cannot sustain life without ongoing transfusions. If the transfusions are preventive rather than survival, the case goes back to A, B, or C.

For patients who meet 7.05D, the case is usually a straightforward approval. Lifelong transfusion dependence with the 6 week schedule documented in the transfusion log is unambiguous. The hematology records will show the date of every transfusion, the units given, and the pre-transfusion and post-transfusion hemoglobin values.

Listing 7.18: the residual case for repeated complications

Many sickle cell patients have real, life-altering disease that does not quite meet 7.05A, B, or C. Maybe they have 4 documented crises rather than 6. Maybe they had 2 hospitalizations rather than 3. Maybe their hemoglobin runs 7.5 to 8.0 rather than dropping to 7.0. For these claimants, the path is Listing 7.18.

Listing 7.18 covers repeated complications of hematological disorders. It requires complications resulting in significant, documented symptoms or signs, and marked limitation in one of three general areas of functioning: activities of daily living, social functioning, or completing tasks because of deficiencies in concentration, persistence, or pace.

This is a more flexible path because it does not require precise counting. A claimant with 4 documented vaso-occlusive crises a year, chronic fatigue keeping daily activities reduced, and difficulty completing tasks due to pain and brain fog can meet 7.18 even if 7.05A is not met. The treating hematologist's RFC opinion is critical here.

The downside of 7.18 is that adjudicators are less familiar with it and the "marked limitation" assessment introduces subjectivity. A clean 7.05A approval is faster and more reliable when the records support it. Use 7.18 as the backup path when the counting just barely falls short.

The records that win these cases

Strong 7.05 files share a common set of documents. The first is the hemoglobin electrophoresis report. This is the foundational diagnostic test. It confirms sickle cell disease (HbSS, HbSC, HbS-beta thalassemia) or thalassemia (alpha or beta variants). Without electrophoresis, DDS cannot confirm the underlying diagnosis.

The second is the ER and hospital records for every pain crisis or complication-related visit. For each event, the file needs the date, the chief complaint, the route of narcotic administration (IV vs IM vs oral), the duration of the visit or admission, and the diagnosis. The discharge summary or ER note has all of this when it is well-written.

The third is the hematology consultation note from the treating sickle cell specialist or specialty sickle cell disease center. This note ties everything together. It states the type of sickle cell disease, the crisis frequency, the baseline and crisis hemoglobin values, the complications experienced (acute chest syndrome, avascular necrosis, stroke history, pulmonary hypertension, renal involvement), and the current treatment regimen (hydroxyurea, voxelotor, crizanlizumab, L-glutamine, chronic transfusion, bone marrow transplant if done).

The fourth is the transfusion log if relevant. For 7.05D claims, the log has to show every transfusion with dates and units. For 7.05A and B claims with chronic transfusions, the log supports the severity argument and helps with the residual case.

The fifth is the CBC trend. Three hemoglobin readings of 7.0 g/dL or less spaced 30 days apart meet paragraph C directly. Even when paragraph C is not met, the CBC trend shows the chronicity and severity of the anemia, which strengthens any 7.18 residual case.

The most common reasons 7.05 claims get denied

The first reason is incomplete records. A claimant tells DDS about 8 crises in the past year, but only 4 are in the medical records. The other 4 happened at urgent cares or ERs the claimant did not list, or the records were never requested. DDS counts only what is in the file. If you remember a crisis, find the records before filing.

The second reason is the wrong narcotic route. Many ERs have moved toward oral opioids or non-opioid alternatives for sickle cell crisis management. If your crisis was managed with oral oxycodone instead of IV morphine, it does not meet 7.05A. This is becoming more common as opioid stewardship programs reduce parenteral narcotic use. Talk to your hematologist about whether IV narcotics during severe crises are clinically indicated.

The third reason is the 30 day gap. Two crises 28 days apart count as one for listing purposes. Adjudicators count carefully. If your crises tend to cluster, the listing count drops below 6 even when the symptom burden is high. The residual 7.18 case is your path when this happens.

The fourth reason is the 48 hour rule. Observation stays of 23 or 24 hours do not count. Direct admissions that turn into 36 hour stays do not count. The hospitalization has to last at least 48 hours from arrival to discharge. Some hospitals route sickle cell patients through observation to manage length of stay metrics, which inadvertently kills 7.05B counts.

The fifth reason is incomplete diagnostic confirmation. Without hemoglobin electrophoresis on file, DDS may question the sickle cell diagnosis itself, even when the patient has been treated for the disease for years. If your file does not include an electrophoresis report, get one and have it added.

Worked example: a 34 year old HbSS patient

Let's run a real-style claim. A 34 year old woman with HbSS (homozygous sickle cell) confirmed by electrophoresis at age 1 has had increasingly frequent crises since age 28. Over the past 12 months, the medical records document 7 ER visits for pain crisis, all treated with IV morphine. Three of those visits resulted in inpatient admissions of 3 to 5 days each for acute chest syndrome or severe pain not controlled in the ER.

Her CBCs over the past year show hemoglobin ranging from 7.8 g/dL to 9.2 g/dL, with no readings at or below 7.0. She is on hydroxyurea 1500 mg daily and voxelotor 1500 mg daily. She works part-time as a customer service rep but has missed 14 days of work in the past 6 months due to crises.

Score it against 7.05. Paragraph A: 7 documented vaso-occlusive crises with IV narcotic over 12 months. Check the 30 day spacing. If at least 6 of the 7 are spaced 30 days apart, paragraph A is met. This is a strong listing approval.

Paragraph B: 3 hospitalizations of at least 48 hours, at least 30 days apart, all for sickle cell complications. Also met. Paragraph C is not met because hemoglobin stays above 7.0. Paragraph D is not relevant. The case has two clean paths to approval and the file should highlight both.

If the same patient had only 5 documented crises and 2 hospitalizations, paragraph A would not be met (need 6) and paragraph B would not be met (need 3). The case would pivot to 7.18 with the hematology RFC opinion documenting marked limitation in completing tasks because of pain and fatigue. The work history of 14 missed days in 6 months supports the marked limitation finding.

State-by-state notes

Sickle cell disease prevalence is highest in states with large Black populations. Mississippi, Louisiana, Alabama, Georgia, South Carolina, North Carolina, and Maryland have the highest per-capita rates of sickle cell. New York, Illinois, and California have large absolute numbers due to population size.

DDS approval rates on sickle cell claims vary. New York, California, Massachusetts, and Maryland DDS offices tend to develop the records carefully and approve at the listing level. Texas, Florida, Georgia, and Mississippi tend to deny initial claims at higher rates, often forcing the case to hearing.

Access to specialty sickle cell disease centers is critical. The Maryland, North Carolina, Georgia, and California networks are mature. The Texas, Florida, and Louisiana networks are uneven. If your state has a specialty center, get into the program. The center will produce the kind of records DDS responds to: detailed hematology notes, transfusion logs, CBC trends, and crisis documentation.

State Medicaid coverage for hydroxyurea, voxelotor, and crizanlizumab is generally good because these are FDA-approved sickle cell drugs. State coverage for bone marrow transplant is more uneven and may require travel to a tertiary center.

Related deep dives

• Listing 13.00 cancer
• Listing 14.02 systemic lupus
• Listing 5.06 IBD
• Listing 4.12 peripheral arterial disease

Frequently asked questions